The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
ApexOnco Front Page
Recent articles
10 March 2025
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
31 January 2025
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
30 January 2025
Firce-1 is scrapped after showing dismal response rates and patient deaths.
29 January 2025
But the new focus on a predictive biomarker could cut the market in half.
29 January 2025
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
27 January 2025
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.